Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients
PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects
Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative…
Nabriva Therapeutics has recently announced positive topline results from a Phase 1 trial of XENLETA® (lefamulin) in adult patients. The pharmacokinetic (PK) data and safety profile observed in this trial were consistent with previous studies conducted in healthy subjects. These results provide further support for the potential utility of lefamulin in treating patients with cystic fibrosis.
Lefamulin is a novel antibiotic that has shown promise in the treatment of various bacterial infections. This Phase 1 trial aimed to assess the safety, tolerability, and PK profile of lefamulin in adult patients, with a focus on those with cystic fibrosis. The results of the trial demonstrated that lefamulin was well-tolerated and exhibited a PK profile that was consistent with previous studies in healthy subjects.
These positive topline results are a significant milestone for Nabriva Therapeutics and the development of lefamulin as a potential treatment option for patients with cystic fibrosis. The company is now looking ahead to further clinical trials to continue evaluating the efficacy and safety of lefamulin in this patient population.
How will this affect me?
As a potential future treatment option for patients with cystic fibrosis, the development of lefamulin could have a significant impact on individuals living with this condition. If lefamulin proves to be effective and safe in further clinical trials, it may offer patients a new therapeutic option for managing their symptoms and improving their quality of life.
How will this affect the world?
The development of lefamulin as a potential treatment for cystic fibrosis has the potential to benefit not only individual patients but also the broader healthcare community. By expanding the range of treatment options available for cystic fibrosis, lefamulin could contribute to improved outcomes and quality of life for patients around the world.
Conclusion
The positive topline results from the Phase 1 trial of lefamulin are an encouraging development in the field of cystic fibrosis treatment. Nabriva Therapeutics’ continued research and development efforts hold promise for the future of patients with this condition, and the potential impact of lefamulin on both individuals and the global healthcare community is significant.
